ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
| Revenue (Most Recent Fiscal Year) | $426.45M |
| Net Income (Most Recent Fiscal Year) | $197.67M |
| PE Ratio (Current Year Earnings Estimate) | 22.69 |
| PE Ratio (Trailing 12 Months) | 24.61 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.09 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 26.83 |
| Pre-Tax Margin (Trailing 12 Months) | 31.89% |
| Net Margin (Trailing 12 Months) | 42.87% |
| Return on Equity (Trailing 12 Months) | 36.52% |
| Return on Assets (Trailing 12 Months) | 26.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.18 |
| Inventory Turnover (Trailing 12 Months) | 1.21 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.16 |
| Earnings per Share (Most Recent Fiscal Year) | $0.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 238.63M |
| Free Float | 229.80M |
| Market Capitalization | $3.46B |
| Average Volume (Last 20 Days) | 3.81M |
| Beta (Past 60 Months) | 0.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |